🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

421 results for “Pari” Clear

  1. OPDIVO 10 mg/mL concentrate for solution for infusion., Kymriah 1.2 x 10^6 – 6 x 10^8 cells dispersion for infusion

    Pari Pharma GmbH

    children, adolescents and young adults with Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  2. Ofev 100 mg soft capsules, Ofev 150 mg soft capsules

    Pari Pharma GmbH

    Adult patients aged 18 and over with unicentric hyalino-vascular Castleman's disease

    phase 2 small molecule active

    1 trial

  3. Olaparib

    United Therapeutics Europe Ltd

    Bile Duct Adenocarcinoma

    phase 2 small molecule active

    1 trial

  4. Olaparib Continuous (28-Day cycle) 300 mg BD.

    AstraZeneca

    Metastatic Triple Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  5. Olaparib, ETOPOSIDE TEVA 20 mg/ml, concentrato per soluzione per infusione, Cisplatino Sandoz 1 mg/ml – Concentrato per soluzione per infusione, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Olaparib, CARBOPLATINO TEVA 10 mg/ml

    Istituto Gentili S.r.l.

    Extensive-Stage Small-Cell Lung Cancer (ES SCLC)

    phase 2 small molecule active

    1 trial

  6. Olaparib, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Olaparib

    The George Institute

    Undifferentiated pleomorphic sarcoma and Dedifferentiated liposarcoma

    phase 2 small molecule active

    1 trial

  7. Olaparib, Olaparib, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Disc Medicine

    Colorectal cancer

    phase 2 small molecule active

    1 trial

  8. Olumiant 2 mg film-coated tablets, Olumiant 4 mg film-coated tablets

    Pari Pharma GmbH

    -women with an inflammatory HCA proven at histology and with at least one inflammatory HCA of more than 5 cm. -male with at least one inflammatory HCA proven at histology whatever the size and considered as non resectable by the multidisciplinary tumor board

    phase 2 small molecule active

    1 trial

  9. Opevesostat, -, CABAZITAXEL , -, FLUDROCORTISONE , Olaparib, HYDROCORTISONE , DEXAMETHASONE , -, -, -, -, Olaparib, DOCETAXEL , -

    Merck Sharp and Dohme

    Metastatic castration resistant prostate cancer (mCRPC)

    phase 2 small molecule active

    1 trial

  10. Oxaliplatin 5 mg/ml concentrate for solution for infusion, TEMOZOLOMIDE, TRAMETINIB, DISODIUM FOLINATE, Capecitabine Accord 300 mg film-coated tablets, Temozolomide SUN 5 mg hard capsules, RUCAPARIB, Mekinist 0.5 mg film-coated tablets, Temozolomide SUN 140 mg hard capsules, REGORAFENIB, Capecitabine Accord 300 mg film-coated tablets, TEMOZOLOMIDE, TEMOZOLOMIDE, Temozolomide SUN 20 mg hard capsules, RUCAPARIB, CABOZANTINIB, Capecitabine Accord 300 mg film-coated tablets, CABOMETYX 40 mg film-coated tablets,

    Bristol-Myers Squibb Australia Pty Ltd

    Pan tumor

    phase 2 small molecule active

    1 trial

  11. Oxbryta 500 mg film-coated tablets

    Pari Pharma GmbH

    sickle cell disease

    phase 2 small molecule active

    1 trial

  12. PEMBROLIZUMAB

    Pari Pharma GmbH

    Kaposi's sarcoma

    phase 2 small molecule active

    1 trial

  13. PEMBROLIZUMAB, OLAPARIB, OLAPARIB

    The George Institute

    patients with unresectable or metastatic HER2 negative breast cancer and a deleterious germline mutation in BRCA 1/2, ATM, BARD1, CHEK2, FANCC, PALB2, RAD51C, RAD51D, SLX4, XRCC2 or a homologous recombination deficiency

    phase 2 small molecule active

    1 trial

  14. PREDNISOLONE , MabThera 100 mg concentrate for solution for infusion, PREDNISONE , MabThera 500 mg concentrate for solution for infusion

    Pari Pharma GmbH

    Minimal Change Nephrotic Syndrom

    phase 2 small molecule active

    1 trial

  15. PREDNISONE, PREDNISOLONE, BOSENTAN

    Pari Pharma GmbH

    Newly diagnosed or relapsing Giant-cell arteritis

    phase 2 small molecule active

    1 trial

  16. PROLEUKIN 18 millions U.I., poudre pour solution injectable, CHLORURE DE SODIUM 0,9 % B. BRAUN, solution injectable en ampoule

    Pari Pharma GmbH

    Alzheimer Disease

    phase 2 small molecule active

    1 trial

  17. Pariglasgene brecaparvovec

    Lacuna Pharma Pty Ltd

    Glycogen storage disease type Ia

    phase 2 small molecule active

    1 trial

  18. Peptide A49 associated to melanin, Peptide A52 associated to melanin, Litenimod solution

    Pari Pharma GmbH

    glioblastoma

    phase 2 small molecule active

    1 trial

  19. Placebo d'amiloride, AMILORIDE, AMILORIDE

    Pari Pharma GmbH

    Patients treated with lithium carbonate for a bipolar disorder treated for at least 5 years and with a urine concentration defect.

    phase 2 small molecule active

    1 trial

  20. Placebo de macitentan 10 mg, MACITENTAN

    Pari Pharma GmbH

    Inoperable Chronic thromboembolic pulmonary hyperTension, Pneumology

    phase 2 small molecule active

    1 trial

  21. Placebo of leflunomide, Arava 20 mg film-coated tablets, Mycophenolate mofetil Teva 500 mg film-coated tablets, Placebo of mycophenolate mofetil, Placebo of hydroxychloroquine, PLAQUENIL 200 mg, comprimé pelliculé

    Pari Pharma GmbH

    Primary Sjogren's syndrome

    phase 2 small molecule active

    1 trial

  22. Psilocybin 25 mg Capsules, TRITTICO 60 mg/ml gocce orali, soluzione, PCB2 (Placebo of psilocybin 25mg), Trazodone placebo (pharmaceutical master preparation prepared according to the Good Pharmacy Practice)

    Pari Pharma GmbH

    Treatment-resistant depression

    phase 2 small molecule active

    1 trial

  23. RAVICTI 1.1 g/ml oral liquid

    Pari Pharma GmbH

    Pyruvate dehydrogenase deficiency

    phase 2 small molecule active

    1 trial

  24. RIFAMPICIN , TEDIZOLID PHOSPHATE, ISONIAZID , ETHAMBUTOL , PYRAZINAMIDE , RIFAMPICIN, PYRAZINAMIDE AND ISONIAZID, LINEZOLID

    Pari Pharma GmbH

    first suspected infection with Mycobacterium tuberculosis in the lungs

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources